Aeglea BioTherapeutics
first potential therapy to normalize plasma arginine levels in | Aeglea BioTherapeutics
Company
Deck Type
Sector
Industry
Deck date
December 2021
Slide
15 of 23
Similar slides by Aeglea BioTherapeutics
See diffirences between slides (animation)
Results
December 2021
first potential therapy to normalize plasma arginine levels in | Aeglea BioTherapeutics
Related slides by other companies
DICE Therapeutics
Results
March 2023
confirmed dose dependent target engagement and biological activity | DICE Therapeutics
Goldman Sachs
Investment Banking
October 2016
despite us listings there is substantial shareholder overlap at the firm level vss vent | Goldman Sachs
Other recent decks by Aeglea BioTherapeutics
See all presentations (14 decks)
Investor Presentation
October 2023
Investor Presentation
October 2023
Investor Presentation
September 2023
Investor Presentation
July 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io